Yissum - Research Development Company of the Hebrew University

Synthetic Cannabinoids and Unique Human Endo-cannabinoids for Fighting Bacterial and Fungal Infections

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

new concepts in fighting both bacterial and fungal infections, accumulations and pathogenicity
Project ID : 6-2018-4547

Description of the technology


  • Bacteria communicate and coordinate population behavior through the mechanism of quorum sensing (QS), which controls the expression of genes that affect a variety of bacterial processes.
  • Cannabis, Cannabinoids and endo-cannabinoids can act as novel anti-microbial agents affecting pathogens both in planktonic and biofilm environments.
  • Their effect on bacterial QS has never been investigated.

Our Innovation

A novel concept for fighting bacterial and fungal infections, accumulations and pathogenicity using synthetic cannabinoids and/or human endo-cannabinoids

Applications for use

  • Practical implications against topical infections (as dermal infections), oral infections, internal bacterial/fungal infections and infections associated with indwelling procedures (as catheters).
  • Enable the manipulation of bacterial properties that are of major importance in industry, agriculture and medicine.


  • QS Mechanism is based on small signaling molecules, termed autoinducers (AIs), which control factors such as bioluminescence, pigment production, motility and biofilm formation, among many others.
  • The QS, free-living marine bacterium Vibrio harveyi produces and responds to at least three distinct AIs: HAI-1, AI-2 and CAI-1. AI-2 Is referred to "universal autoinducer" as it is found in numerous Gram-positive and Gram-negative bacteria.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Doron Steinberg
HUJI, Faculty of Dental Medicine
Institute of Dental Sciences

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • infectious diseases

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.